This document provides information on occupational exposure prophylaxis (PEP) for HIV. It discusses the history and effectiveness of PEP, risk factors for HIV transmission after exposure, recommended PEP regimens, and follow-up procedures. The key points are:
- PEP using antiretroviral drugs can reduce the risk of HIV infection after a significant exposure by up to 81%.
- The recommended PEP regimen depends on factors like the severity of exposure and HIV status/viral load of the source patient. Basic regimens include 2 drugs while more severe exposures may warrant a 3 drug expanded regimen.
- Proper wound care and timely reporting of exposures and initiation of PEP within hours of exposure are important to reduce the
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus that emerged in 2019 and causes coronavirus disease2019(COVID-19).1,2 SARS-CoV-2ishighlycontagious.Itdiffers from other respiratory viruses in that it appears that human-tohuman transmission occurs approximately 2 to 10 days prior to the individual becoming symptomatic.2–4 The virus is transmitted from person to person through respiratory secretions. Large droplets from coughing, sneezing or rhinorrhoea land on surfaces within 2 m of the infected person. SARS-CoV-2 remains viable for at least 24 hours on hard surfaces and up to 8 hours on soft surfaces.5 The virus is transferred to another person through hand contact on a contaminated surface followed by touching the mouth, nose or eyes. Aerosol airborne infected particles created during a sneeze or cough remain viable in the air for3 hours.5 These airborne particles of SARS-CoV2 can then be inhaled by another person or land on the mucosal membranes of the eyes.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus that emerged in 2019 and causes coronavirus disease2019(COVID-19).1,2 SARS-CoV-2ishighlycontagious.Itdiffers from other respiratory viruses in that it appears that human-tohuman transmission occurs approximately 2 to 10 days prior to the individual becoming symptomatic.2–4 The virus is transmitted from person to person through respiratory secretions. Large droplets from coughing, sneezing or rhinorrhoea land on surfaces within 2 m of the infected person. SARS-CoV-2 remains viable for at least 24 hours on hard surfaces and up to 8 hours on soft surfaces.5 The virus is transferred to another person through hand contact on a contaminated surface followed by touching the mouth, nose or eyes. Aerosol airborne infected particles created during a sneeze or cough remain viable in the air for3 hours.5 These airborne particles of SARS-CoV2 can then be inhaled by another person or land on the mucosal membranes of the eyes.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
PEP FINAL.ppt
1.
2. “An Ounce of Prevention…
… is worth a pound of cure.” –B. Franklin
3. Categories of HIV Exposure Prophylaxis
(“..the last shall be first.” –Matthew 19:30)
Similar to our understanding of HIV/AIDS
-Starting with AIDS and working back to
HIV (a RETRO-virus)
-Starting with PCP treatment, back to
TMP/SMX prophylaxis
Post-Exposure (PEP - Occupational, Maternal
to Child – a forecast of Pre?)
Post-Exposure (nPEP – Non-Occupational)
Pre-Exposure (PREP - ?Both)
5. History
ZDV FDA-approved to treat HIV, March 1987
CDC publishes first PEP statement 1990; no
specific recommendations
1995 case-control study shows 79% reduction
when ZDV used post-exposure
Guidelines published 1996
Recommended combination antiretroviral
therapy for high-risk significant exposures
6. Prevention
The most effective approach is not to put
yourself at risk at all!!
Use good infection control procedures at all
times
Wear gloves if you are likely to be contaminated
with body fluids (take gloves with you)
Think about what you will do in the event of an
injury before it happens
7. HIV is Fragile
Common substances, including hot water, soap,
bleach and alcohol, will kill it.
Air dries the fluid that contained the virus
which destroys the virus within a few hours
How long HIV can survive outside the body
depends on
*the amount of HIV present in the body fluid;
*what conditions the fluid is subjected to
8. Risk after exposure
Risk of acquiring HIV infection following
occupational exposure to HIV infected blood
is low.
Average risk for HIV transmission after
percutaneous exposure to HIV infected blood
in healthcare settings is approx 1 per 300
After mucocutaneous exposure, <1 in 1000.
No risk of transmission where intact skin is
exposed to HIV infected blood
9. Calculating HIV seroconversion risk
after needlestick/sharps injury
Known HIV+. Risk is 1 in 300
HIV serostatus unknown - where prevalence of
HIV in local/hospital population is:
– 1 in 3 (ie 30%). Risk is 300 x 3 = 1 in 900
– 1 in 10 (ie 10%). Risk is 300 x10 = 1 in 3000
– 1 in 100 (ie 1%). Risk is 300 x 100 = 1 in 30,000
10. Risk of Transmission
Significant exposures to any of the following may
pose a risk for bloodborne pathogen (BBP)
transmission:
Blood, Semen, Vaginal secretions, Cerebrospinal
fluid, Synovial fluid, Pleural fluid, Peritoneal
fluid, Pericardial fluid, Amniotic fluid
Body fluids NON-risk if no visible blood include
urine, sputum, saliva, stool, emesis, nasal
discharge, tears, sweat
Exposure/Transmission Risk varies by pathogen:
(3,33,333)
HIV: 0.3% = 3/1,000, Hep C: 3% = 30/1,000,
Hep B: 30% = 300/1,000
11. PEP – occupational exposure
Four factors associated with an increased risk of
occupationally acquired HIV infection:
1. Deep injury
2. Visible blood on the device which caused the
injury
3. Injury with a needle from artery or vein
4. Terminal HIV illness in source patient
Almost all reported cases of HIV seroconversion have
occurred after injuries with hollow bore needles.
12. Body fluids and materials which may pose a
risk of HIV transmission
Amniotic fluid
Cerebrospinal fluid
Human breast milk
Pericardial fluid
Peritoneal fluid
Pleural fluid
Saliva in association with
dentistry
Synovial fluid
Unfixed human tissues and
organs
Vaginal secretions
Semen
Any other fluid if visibly
bloodstained
Fluid from burns or skin
lesions
14. HIV: Seroconversion in Health Care
Workers
Primary HIV Infection
- Experienced in 81% of HCWs
- Occurred median 25 days after exposure
Seroconversion
- Exposure to seroconversion median 46 days
- Seroconversion by 6 months in 95% of HCWs
- 3 persons with seroconversion at 6-12 months
15. Risk Factors for HIV Seroconversion in
HCWs
Risk Factor Adjusted Odds
Ratio*
Deep Injury 15.0
Visible Blood on Device 6.2
Terminal Illness in Source Patient 5.6
Needle in Source Vein/Artery 4.3
PEP with Zidovudine (AZT) 0.2
*All Risk Factors were significant (P <
0.01)
16. Risk Assessment of Occupational Exposure
Ideally this should not be done by the injured
Health care Worker
Assessment of the injury involves
– Nature of the injury - was there significant
contamination?
– The risk the patient has HIV (Hep C,Hep
B)
• Known HIV+
• Person of unknown HIV serostatus
17. Circumstances of exposure
– Assess if exposure was significant
Types of exposure with contaminated
instruments/body fluids associated with
significant risk
1. Percutaneous injury (needles,
instruments, bites which break skin)
2. Exposure of broken skin (abrasions, cuts)
3. Exposure of mucous membranes inc. the
eye, mouth
Risk Assessment of Occupational Exposure
18. The Source Patient
If of unknown HIV serostatus - A designated
doctor should approach the source patient
and ask for informed agreement to HIV
testing (This should not be the exposed
worker)
Risk Assessment of Occupational Exposure
19. Evaluate the source and the exposure
Is the source material blood or
instrument contaminated with blood or
potentially infectious material?
YES
NO No PEP needed
What type of exposure occurred?
Percutaneous exposure
Intact skin
Mucous membrane or non intact skin
No PEP needed
Assess volume Assess volume
Small
Few drops and/or short
duration
Large
Several drops, major
blood splash and/or long
duration of several
minutes or more
Less severe
Solid needle,
superficial scratch
More severe
Large bore hollow needle ,
deep puncture, visible
blood on device, source
needle used in artery or
vein.
20. PEP Steps
1:Manage the injury
2:Report and record the incident
3:Evaluate the exposed person
4:Evaluate the source patient
5:PEP
6:follow up
21. Universal Precautions
Refers to a method of infection control in which
all human blood and other potentially
infectious materials are treated as if known to
be infectious for HIV and HBV and HCV.
Universal precautions do not apply to feces,
nasal secretions, sputum, sweat, tears, urine
or vomitus unless they contain visible blood.
22. Universal Precautions
Using protective equipment when applicable, to
protect the skin and mucous membranes.
The mandatory use of gloves, gowns, masks
and eye protection if any worker is handling
bio-hazardous waste.
The washing of hands after handling bio-
hazardous waste.
23. Immediate action following a
contamination incident
Wound or non-intact skin to be washed liberally
with soap and water without scrubbing
Antiseptics should not be used as no evidence of
efficacy and effect on local defences
unknown
Free bleeding encouraged
If mucous membranes contaminated - irrigate
with water and remove contact lenses
24. Immediately after exposure to
blood
Flush splashes to the nose, mouth or skin with
water
Irrigate eye with clean water, saline or sterile
irriguants
REPORT the exposure
25. Finding a Needle
HIV can live a long time in a used needle Hep
B and C can live even longer!
Needle sticks can transmit Hepatitis more easily
than HIV
If you find a needle with an exposed point, pick
it up very carefully (with tweezers or tape)
and put it in a sharps container.
27. Post Exposure Protocol
What is your protocol?
1) Needlestick or a cut: washed with soap and water.
Splashes to nose, mouth, or skin: flushed with water.
Eyes: irrigated with sterile water.
2) Report exposure to supervisor.
3) Discuss post-exposure treatment with medical
provider. Hep B: vaccine & HBIG
HIV: Post Exposure Prophylaxis
28. When should PEP be started?
efficacy of PEP thought to wane with time
at what point is PEP “no longer worth it”?
benefits of PEP
risks of PEP
exposure
time
29. Timing of PEP: CDC Guidelines
Initiate as soon as possible (within hours)
Interval after which there is no benefit for
humans is undefined
“If appropriate for the exposure, PEP should
be started even when the interval since
exposure exceeds 36 hours”
Obtain expert advice when interval has
exceeded 36 hours
MMWR 1998;47:RR-7.
30. HIV PEP: Percutaneous Exposure
DHS/PEP Rx/PP
Source Infection Status
Exposure Type
Less Severe
More Severe
HIV+ Class 1
Less Severe: eg. solid needle, superficial injury
More Severe: eg. Large-bore hollow needle, deep puncture, visible blood on device,
or needle used in patient’s artery or vein
Class 1: Asymptomatic or low HIV RNA (<1500)
Class 2: Symptomatic or known high HIV RNA
HIV+ Class 2
Basic (2 Drugs) Expanded (3 Drugs)
Expanded (3 Drugs) Expanded (3 Drugs)
From: CDC. MMWR 2001;50 (RR11):1-42.
31. Post-Exposure HIV Prophylaxis
(PEP)
PEP can reduce the risk of infection up to 81% (CDC,
2001)
DHHS recommends 4-week course, 2 drugs (e.g.
ZDV/3TC or EFV/FTC) for most exposures, or 3
drugs (Add e.g. LPV/r) for high risk exposures, e.g.
large volume of blood, or deep puncture, or known
HIV positive source, or drug-resistant HIV.
Updated U.S. Public Health Service Guidelines for the
Management of Occupational Exposures to HBV,
HCV, and HIV and Recommendations for
Postexposure Prophylaxis, September 26, 2005 /
54(RR-9);1-17. Available online at:
http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=67
32. HIV PEP: Mucous Membrane
Exposure
DHS/PEP Rx/PP
Source Infection Status
Exposure Type
Small Volume
Large Volume
HIV+ Class 1
Class 1: Asymptomatic or low HIV RNA (<1500)
Class 2: Symptomatic or known high HIV RNA
HIV+ Class 2
Consider Recommend
Basic (2 Drugs) Basic (2 Drugs)
Recommend Recommend
Basic (2 Drugs) Expanded(3 Drugs)
From: MMWR 2001;50 (RR-11):1-42.
33. Source of Unknown HIV Status
- Generally, no PEP warranted; however
consider basic 2-drug PEP for sources
with HIV risk factors.
Unknown Source
- Generally, no PEP warranted; however
consider basic 2-drug PEP in settings
where exposure to HIV-infected persons is
likely.
HIV Postexposure Prophylaxis
Source Unknown or Status of Source
Unknown
34. HIV PEP Rx: Basic Regimen
Basic Regimen
Zidovudine (ZDV, AZT) +
Lamivudine (3TC)
300 mg bid or 200 mg tid
150 mg bid
Alternate Basic Regimen
Didanosine (ddI) +
Stavudine (d4T)
Dose
Stavudine (d4T) +
Lamivudine (3TC)
400 mg qd (250 mg qd if < 60 kg)
40 mg bid (30 mg bid if <60 kg)
Dose
200 mg bid (125 mg bid if < 60 kg)
150 mg bid
35. HIV PEP Rx: Expanded Regimen
Expanded Regimen
Basic Regimen + One of Following
Medication
Indinavir (IDV)
Nelfinavir (NFV)
Efavirenz (EFV)
Abacavir (ABC)
800 mg q8h
750 mg tid or 1250 mg bid
600 mg qd
300 mg bid
Dose
36. CTL Responses to HIV Exposure in
HCWs
Situation
HCW exposed to HIV+ source
-Took AZT PEP
-Did not take PEP
HCW exposed to HIV-source
7/20 (35%)
1/7 (14%)
6/13 (46%)
0/20 (0%)
CTL Response
37. Failure of Combination HIV PEP Rx
Regimen
ZDV + ddI
ZDV + ddI
*3 Drugs
ZDV + ddI + 3TC + IDV
ddI + d4T + NVP
Yes
No
Yes (not resistant)
Yes (resistant)
Yes (resistant)
Source on ARV Meds
*ZDV + 3TC + IDV x 48h, then d4T + 3TC + IDV
38. “From a theoretical perspective, risk stratification is
sensible; however, from a practical perspective,
these issues are often murky. For individuals who
believe they have experienced an occupational
HIV exposure, offering less than the presumably
most effective regimen may seem objectionable.
Thus, in our institution (NIH), we tend to offer the
3-drug regimen, including a protease inhibitor....”
- DK Henderson-
39. Occupational HIV Exposure: PEP Follow-
Up
HIV Antibody Testing: Baseline, 6w, 12w, 6m, +/-
12m
Routine use of HIV RNA: not recommended
Drug Toxicity Monitoring: baseline and at 2 weeks
Sexual abstinence or condom use (especially in
first 6-12 weeks after exposure)
Avoid Pregnancy
40. A 39-year-old nurse sticks herself in the finger with
a needle used to draw blood from an HIV-infected
patient. The source patient’s most recent CD4
count was 135 cells/mm
3
and HIV RNA 26,400;
the source patient is on AZT + 3TC + Indinavir
and is about to go on a new regimen.
a) What PEP regimen would you recommend?
41. “If the source-person’s virus is known or
suspected to be resistant to one or more of
the drugs included in the PEP regimen, the
selection of drugs to which the source
patient’s virus is unlikely to be resistant is
recommended.”
- Centers for Disease Control and Prevention-
42. HIV PEP
Current EAGA recommendations for UK Health care
workers seconded overseas:
– In areas where no anti HIV treatment is
available for patients
– 2 Drug combination
– Zidovudine 250mg and Lamivudine
150mg bd (Combivir 1 tablet bd) for 28
days
43. HIV PEP
– BUT
– AntiHIV treatment is being rolled out to the local
population in many developing countries (parts of Uganda,
Malawi, Botswana etc)
– In these areas anti-HIV treatments are likely to be readily
available to staff who have significant occupational injuries
(ask your supervisor!)
– Drug resistant HIV likely to be present in local population
– 3 Drug combination recommended for exposures to
‘treatment experienced’ HIV population
– Zidovudine 250mg + Lamivudine 150mg bd (Combivir 1
tablet bd) + Kaletra 2 tablets bd for 28 days
– PEP should ideally be started within 1 hour of the injury
44. Costs
Combivir 1 bd
– 7 days = £78.96
– 28 days = £315.84
Combivir 1 bd + Kaletra 2 tablets bd
– 7 days = £176.45
– 28 days =£709.63
– Recommend 7 day pack
45. WARNING
The sale of anti HIV drugs, as with any prescription
drugs, to a third party is illegal, may result in
criminal prosecution and proceedings by the
General Medical Council.
Disposal of unused supplies of antiHIV drugs are
recommended on your return to the UK after your
elective. This can be arranged through any
pharmacy.
It is unsafe to purchase or use any drug prescribed for
another person
46. Nelfinavir
This agent was previously recommended and
prescribed as HIV PEP
In the last month it has been withdrawn by the
Roche Pharmaceuticals as some UK supplies
have been contaminated with a carcinogen.
Please hand any supplies of this drug that you
have to any pharmacy for disposal.